Association between Metabolic Disorders and Cholangiocarcinoma: Impact of a Postulated Risk Factor with Rising Incidence

Imagem de Miniatura
Arquivos
art_FONSECA_Association_between_Metabolic_Disorders_and_Cholangiocarcinoma_Impact_of_2022.PDF (618.81 KB)
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2022
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
MDPI
Autores
IZQUIERDO-SANCHEZ, Laura
BANALES, Jesus M.
Citação
CANCERS, v.14, n.14, article ID 3483, 14p, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Simple Summary A potential relationship between cholangiocarcinoma and metabolic disorders has been suggested, but there is a lack of published data. This study aimed to describe the prevalence of metabolic disorders in a cohort of 122 patients with cholangiocarcinoma and report clinical outcomes. We found a prevalence of 42.6% of metabolic disorders. There was no significant difference in overall survival between patients with or without metabolic disorders, although there was a better survival in the subgroup of patients undergoing surgical resection. This indicates a need to better explore the association between cholangiocarcinoma in a metabolic background. Introduction and objectives: The incidence of cholangiocarcinoma (CCA) has been increasing globally. Although a concomitant increase in the incidence of metabolic disorders might suggest a causal relationship, the data are scarce. We aimed to describe the prevalence of metabolic disorders in patients with CCA and report the clinical features and outcomes. Patients and Methods: Retrospective study including patients with CCA. Patients were divided into: (1) past history of diabetes or/and overweight/obesity (""metabolic disorder group"") and (2) without any of these features (""non-metabolic-disorder group""). A Cox regression model was used to determine the prognostic factors. Results: 122 patients were included. In total, 36 (29.5%) had overweight/obesity, 24 (19.7%) had diabetes, and 8 (6.6%) had both. A total of 29 (23.8%) patients had resectable disease and received upfront surgery. A total of 104 (85.2%) received chemotherapy for advanced/recurrent disease. The overall survival of the cohort was 14.3 months (95% CI: 10.1-17.3). ECOG-PS 0 (p < 0.0001), resectable disease (p = 0.018) and absence of vascular invasion (p = 0.048) were independently associated with better prognosis. The ""metabolic disorder group"" (n = 52) had a median survival of 15.5 months (95% CI 10.9-33.9) vs. 11.5 months (95% CI 8.4-16.5) in the ""non-metabolic-disorder group"" (n = 70) (HR: 1.10; 95% CI 0.62-1.94). Patients with resectable disease in the ""metabolic group"" had longer survival than patients in the ""non-metabolic group"" (43.4 months (95% CI 33.9-NR) vs. 21.8 months (95% CI 8.6-26.9); HR = 0.12, 95% CI 0.03-0.59). Conclusion: Metabolic disorders are frequent among CCA patients. Underlying metabolic comorbidities may be associated with prognosis in resectable CCA. There is a need to explore the mechanism that drives CCA carcinogenesis in a metabolic background.
Palavras-chave
liver cancer, cholangiocarcinoma, metabolic syndrome, diabetes, obesity
URI
https://observatorio.fm.usp.br/handle/OPI/48581
Referências
  1. Anstee QM, 2013, NAT REV GASTRO HEPAT, V10, P330, DOI 10.1038/nrgastro.2013.41
  2. Banales JM, 2020, NAT REV GASTRO HEPAT, V17, P557, DOI 10.1038/s41575-020-0310-z
  3. Bekki Y, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.776863
  4. Berres ML, 2010, DIGEST DIS, V28, P192, DOI 10.1159/000282085
  5. Boyce CJ, 2010, AM J ROENTGENOL, V194, P623, DOI 10.2214/AJR.09.2590
  6. Chaiteerakij R, 2013, HEPATOLOGY, V57, P648, DOI 10.1002/hep.26092
  7. Chan KM, 2018, BMC GASTROENTEROL, V18, DOI 10.1186/s12876-018-0912-x
  8. Da Fonseca L.G., 2021, ANN HEPATOL, V24, P100376, DOI [10.1016/j.aohep.2021.100376, DOI 10.1016/J.AOHEP.2021.100376]
  9. De Lorenzo S, 2020, CANCERS, V12, DOI 10.3390/cancers12113182
  10. Djiogue S, 2013, ENDOCR-RELAT CANCER, V20, pR1, DOI 10.1530/ERC-12-0324
  11. Eslam M, 2020, GASTROENTEROLOGY, V158, P1999, DOI 10.1053/j.gastro.2019.11.312
  12. Fava G, 2008, CANCER RES, V68, P6752, DOI 10.1158/0008-5472.CAN-07-6682
  13. Foerster F, 2022, J HEPATOL, V76, P446, DOI 10.1016/j.jhep.2021.09.007
  14. Garcia-Jimenez C, 2014, J MOL ENDOCRINOL, V52, pR51, DOI 10.1530/JME-13-0152
  15. Ghidini M, 2021, EXPERT REV GASTROENT, V15, P999, DOI 10.1080/17474124.2021.1946393
  16. Graffy PM, 2019, RADIOLOGY, V293, P334, DOI 10.1148/radiol.2019190512
  17. Huang YN, 2017, ONCOTARGET, V8, P100570, DOI 10.18632/oncotarget.20141
  18. Izquierdo-Sanchez L, 2022, J HEPATOL, V76, P1109, DOI 10.1016/j.jhep.2021.12.010
  19. Khan SA, 2019, LIVER INT, V39, P19, DOI 10.1111/liv.14095
  20. Kuriyama K, 2020, CANCER SCI, V111, P1969, DOI 10.1111/cas.14421
  21. Lamarca A, 2021, LANCET ONCOL, V22, P690, DOI 10.1016/S1470-2045(21)00027-9
  22. Molinari M., 2021, ANN SURG, V2, pe065, DOI [10.1097/AS9.0000000000000065, DOI 10.1097/AS9.0000000000000065]
  23. Nagtegaal ID, 2020, HISTOPATHOLOGY, V76, P182, DOI 10.1111/his.13975
  24. Neuschwander-Tetri BA, 2010, HEPATOLOGY, V52, P774, DOI 10.1002/hep.23719
  25. Oh DY, 2022, J CLIN ONCOL, V40, DOI 10.1200/JCO.2022.40.4_suppl.378
  26. Pfister D, 2021, NATURE, V592, P450, DOI 10.1038/s41586-021-03362-0
  27. Surapaneni PK, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.4_suppl.288
  28. Valle JW, 2016, ANN ONCOL, V27, pv28, DOI 10.1093/annonc/mdw324
  29. Valle J, 2010, NEW ENGL J MED, V362, P1273, DOI 10.1056/NEJMoa0908721
  30. Welzel TM, 2007, INT J CANCER, V120, P638, DOI 10.1002/ijc.22283
  31. Welzel TM, 2007, CLIN GASTROENTEROL H, V5, P1221, DOI 10.1016/j.cgh.2007.05.020
  32. Wijarnpreecha K, 2020, J GASTROINTEST LIVER, V29, P629, DOI 10.15403/jgld-2990
  33. Xiong JP, 2018, CANCER MANAG RES, V10, P3849, DOI 10.2147/CMAR.S175628
  34. Yang H, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00854

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - FM/MGT
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - HC/InRad
Carregar mais